November 25, 2019
2 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: New agent reduces hyperemia in dry eye disease
ORLANDO, Fla. – Kala Pharmaceuticals’ KPI-121 0.25% significantly and rapidly reduced conjunctival hyperemia in three clinical trials, Walt Whitley, OD, said here at the American Academy of Optometry meeting.
More than 1,900 patients were enrolled, and they experienced no adverse events, he said.
Disclosure: Whitley reports he is a consultant for Kala.